Swiss National Bank’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Swiss National Bank’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-50,100	Closed	-$5.38M	–	2687
2023 Q1	$5.38M	Sell	50,100 -6,000	-11%	-$691K	﹤0.01%	1223
2022 Q4	$6.17M	Buy	56,100 +33,100	+144%	+$2.15M	﹤0.01%	1188
2022 Q3	$1.36M	Hold	23,000	–	–	﹤0.01%	2144
2022 Q2	$649K	Sell	23,000 -4,600	-17%	-$133K	﹤0.01%	2544
2022 Q1	$1.04M	Buy	27,600 +1,900	+7%	+$75.1K	﹤0.01%	2387
2021 Q4	$1.02M	Buy	+25,700	New	+$805K	﹤0.01%	2473

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Swiss National Bank's RXDX Position: Q2 2023 in Review

Swiss National Bank sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 50,100 shares — an estimated $5.38M sold.

Swiss National Bank first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $6.17M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Swiss National Bank reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Swiss National Bank sold 50,100 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $5.38M.
Swiss National Bank first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Swiss National Bank's Prometheus Biosciences, Inc. Common Stock position peaked at $6.17M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Swiss National Bank's 13F filing for Q2 2023, filed 9 Aug 2023.